TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.

Authors: Giuseppe Lo Russo, Margarita Majem, Kenneth John O'Byrne, Thorsten Oliver Goetze, Christian Mueller, Frederic Triebel

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8668

Source: Full article

TPS8668